Quidel

Quidel Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Quidel (QDEL) as of Nov 6, 2026 is 74.75. In the previous year, Cash Conversion Cycle (CCC) was 70.18 — a change of 6.53% (higher).

Cash Conversion Cycle

74.75

YoY

6.53%

Last updated:

Cash Conversion Cycle (CCC) of Quidel is 2025 74.75 . Cash Conversion Cycle (CCC) of Quidel was 2024 70.18 . It decreases by 6.53% higher compared to the previous year.

The Quidel Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
115.60 USD
Jan 1, 2019
117.99 USD
Jan 1, 2020
144.91 USD
Jan 1, 2021
165.72 USD
Jan 1, 2022
66.09 USD
Jan 1, 2023
111.38 USD
Jan 1, 2024
70.18 USD
Jan 1, 2025
74.75 USD
The Quidel Cash Conversion Cycle history
YEARCash Conversion CycleYoY
74.75+6.53%
70.18-37.00%
111.38+68.52%
66.09-60.12%
165.72+14.37%
144.91+22.81%
117.99+2.07%
115.60-44.29%
207.51+113.20%
97.33-21.78%
124.43-4.05%
129.68—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quidel Stock analysis

What does Quidel do? Quidel Corporation is a US-based company specializing in the production of rapid tests for medical diagnostics. It was founded in 1979 and is headquartered in San Diego, California. Since 1991, it has been listed on the NASDAQ stock exchange. Quidel initially started as Diagnostic Reagents Laboratory (DRL) and focused on manufacturing diagnostic products for the veterinary sector. In 1990, it was renamed Quidel Corporation and expanded its operations into human diagnostics. The company's business model revolves around the development and production of immunological rapid tests that can quickly and easily diagnose infectious diseases and other health problems. Quidel focuses on creating high-quality, accurate, and cost-effective test procedures that can be used by healthcare professionals or even laypersons at home. One of Quidel's core competencies is bringing to market rapid tests that are easy to perform and provide immediate results without the need to send samples to a laboratory. The company offers a wide range of rapid tests for diagnosing various diseases. These include tests for infectious diseases such as influenza, streptococcus, Lyme disease, and chlamydia, as well as tests for pregnancy, drug abuse, and cardiovascular diseases. The tests are available as single tests or panel tests that can diagnose multiple diseases simultaneously. Quidel operates in four business segments: Molecular Diagnostics, Point-of-Care Diagnostics, Immunoassays, and Specialized Diagnostic Solutions. The Molecular Diagnostics segment focuses on developing molecular diagnostic tests and instruments for laboratory use. The Point-of-Care Diagnostics segment develops and produces rapid tests for use in medical practices and hospitals. The Immunoassays segment specializes in reagent-based tests for the quantitative analysis of biomolecules. The Specialized Diagnostic Solutions segment includes specialized diagnostic products, such as test systems for monitoring antibiotic therapies. In conclusion, Quidel Corporation specializes in the development and production of rapid tests for medical diagnostics. The company offers a wide range of high-quality, accurate, and cost-effective test procedures for diagnosing infectious diseases, pregnancy, drug abuse, and cardiovascular diseases. Quidel has gained a significant market share in the diagnostics field through its rapid tests and diverse range of test panels for various conditions, and it is known for its innovative products. Quidel is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Quidel stock

Cash Conversion Cycle (CCC) of Quidel is 74.75 in 2025.

Cash Conversion Cycle (CCC) of Quidel changed from 70.18 to 74.75, representing a 6.53% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Quidel since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Quidel with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Quidel

All Key Metrics — Quidel